Hi all,As part of IBX’s Annual General Meeting (held today)...

Hi all,

As part of IBX’s Annual General Meeting (held today) Chair and CEO, Bob Proulx, reviewed the Company’s achievements of the past year, and the outlook for the year ahead.

We are proud of our work having successfully designed, gained approval for, made product for, and initiated our first human clinical trial for our MagSense® HER2 Breast Cancer imaging agent in 2020. With our first patient enrolled in the clinical trial this week and new sites participating, Imagion and our investigators remain confident we will reach our recruitment target for the study.

Additionally, expanding our R&D pipeline of targeted imaging agents through collaborations with Monash University, Patrys and others is enabling the exploration of further indications, which, combined with the Phase I data, should better position us to attract strategic development and commercial relationships.

Read our Executive Chairman and CEO Bob Proulx’s AGM remarks here.